Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension

British Journal of Psychiatry

Volumn 200, Issue 1, 2012, Pages 68-73

  Ginsberg, Ylva ^a   Lindefors, Nils ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; OSMOTIC RELEASE ORAL SYSTEM METHYLPHENIDATE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; HEADACHE; HUMAN; MALE; MUCOSAL DRYNESS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRISONER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNCONSCIOUSNESS;

ADULT; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; INTENTION TO TREAT ANALYSIS; INTERVIEW, PSYCHOLOGICAL; MALE; METHYLPHENIDATE; MIDDLE AGED; OSMOSIS; PLACEBOS; PRISONERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84855559831     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.111.092940     Document Type: Article

References (29)

1. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194: 204-11.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
3. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8. (Pubitemid 30249663)
4. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ 2005; 47: 565-72. (Pubitemid 40847440)
5. Hammerness P, Surman C, Miller K. Update on adult attention-deficit/ hyperactivity disorder. Curr Neurol Neurosci Rep 2008; 8: 484-9.
6. Rosler M, Casas M, Konofal E, Buitelaar J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 2010; 5: 684-98.
7. Eme RF. Attention-deficit/hyperactivity disorder and correctional health care. J Correct Health Care 2009; 5: 5-18.
8. Ginsberg Y, Hirvikoski T, Lindefors N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry 2010; 10: 112.
9. Rosler M, Retz W, Retz-Junginger P, Hengesch G, Schneider M, Supprian T, et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004; 254: 365-71. (Pubitemid 40192991)
10. Young SJ, Adamou M, Bolea B, Gudjonsson G, Muller U, Pitts M, et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statment from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry 2011; 11: 32.
11. Gudjonsson GH, Wells J, Young S. Personality disorders and clinical syndromes in ADHD prisoners. J Atten Disord 2010; Oct 26 (Epub ahead of print).
12. Young S, Wells J, Gudjonsson G. Predictors of offending among prisoners: the role of attention-deficit hyperactivity disorder and substance use. J Psychopharmacol 2010; Jun 17 (Epub ahead of print).
13. National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE, 2009 (http://guidance.nice.org.uk/CG72/NICEGuidance/).
14. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-9. (Pubitemid 38134162)
15. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. Limits of metaanalysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23: 733-44.
16. Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009; 12: 449-59.
17. Bejerot S, Ryden EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry 2010; Jun 1 (Epub ahead of print).
18. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebocontrolled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259: 120-9.
19. Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2010; 15: 36-45.
20. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother 2010; 18: 75-9.
21. Hare RD, Clark D, Grann M, Thornton D. Psychopathy and the predictive validity of the PCL-R: an international perspective. Behav Sci Law 2000; 18: 623-45. (Pubitemid 32006048)
22. Rosler M, Retz W, Stieglitz RD. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations - benchmarking instruments for international multicentre trials. Pharmacopsychiatry 2010; 43: 92-8.
23. Guy W. Clinical Global Impressions. US Department of Health and Human Services, 1976.
24. Ramirez A, Ekselius L, Ramklint M. Axis V - Global Assessment of Functioning scale (GAF), further evaluation of the self-report version. Eur Psychiatry 2008; 23: 575-9.
25. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolongedrelease OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2008; 63: 981-9.
26. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 456-63. (Pubitemid 40311979)
27. Surman CB, Monuteaux MC, Petty CR, Faraone SV, Spencer TJ, Chu NF, et al. Representativeness of participants in a clinical trial for attention-deficit/ hyperactivity disorder? Comparison with adults from a large observational study. J Clin Psychiatry 2010; 71: 1612-6.
28. Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, et al. Predictors of treatment outcome in adults with ADHD treated with OROS methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 554-60.
29. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 37-48.